AHA 2023 — Investigator, Prof Stefan James, Prof Jonas Oldgren (Uppsala University, SE) and Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) discuss the findings of the DAPA-MI trial (NCT04564742).

This multicenter, parallel-group, registry-based, randomized, double-blind and placebo-controlled phase 3 trial (AstraZeneca) investigated the effect of dapagliflozin 10 mg vs placebo, given once daily in addition to standard of care therapy (SoC), on death, hospitalization for HF (HHF) and other cardiometabolic outcomes. 

4017 patients were enrolled in the study which excluded participants with known diabetes.

Results presented at AHA 2023 showed that dapagliflozin demonstrated significant benefit in patients with acute MI and impaired left ventricular systolic dysfunction, without diabetes or CHF in regards to improvement in cardiometabolic outcomes as compared to placebo. This effect was consistent across all prespecified subgroups, with no new safety concerns. Clinical event rates were low with no significant difference between randomized groups.

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

This is an independent interview conducted by Radcliffe Cardiology.

For more content from #AHA23 head to the Late-Breaking or the CardioNerds Conference Scholars Collection.

Support: This is an independent interview produced by Radcliffe Cardiology.

Editors: Mirjam Boros, Jordan Rance
Videographers: Dan Brent, Mike Knight